Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 534 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TDF Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Rectal Safety and Acceptability Study of Tenofovir 1% Gel

NCT01232803
View directory record Official record
Conditions
Rectal Microbicides
Interventions
Tenofovir 1% gel, 2% N-9 gel, HEC Placebo gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 21, 2026, 7:04 AM EDT
Terminated No phase listed Observational Results available

Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

NCT04518228
View directory record Official record
Conditions
HIV, Tuberculosis
Interventions
Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment

NCT01363011
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
E/C/F/TDF, COBI, ATV, DRV, NRTI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 2, 2016 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 21, 2026, 7:04 AM EDT
Completed No phase listed Observational

Evolution of L74V or K65R Mutations in VIremic Subjects on Tenofovir Disoproxil Fumarate (TDF) or Abacavir (ABC) (EVITA)

NCT00312169
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Orlando Immunology Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Fresno, California • Los Angelos, California • Tarzana, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 21, 2026, 7:04 AM EDT
Active, not recruiting Phase 4 Interventional

Immediate Initiation of Antiretroviral Therapy During "Hyperacute" HIV Infection

NCT02656511
View directory record Official record
Conditions
HIV
Interventions
Dolutegravir, Emtricitabine/Tenofovir
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 21, 2026, 7:04 AM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Viread in Antiretroviral Naïve Patients

NCT00679926
View directory record Official record
Conditions
HIV Infections
Interventions
Once daily
Drug
Lead sponsor
Oklahoma State University Center for Health Sciences
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 4 Interventional Results available

Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)

NCT03126370
View directory record Official record
Conditions
Hepatitis C, HIV Coinfection
Interventions
TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women

NCT02357602
View directory record Official record
Conditions
Healthy
Interventions
GS-7340
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF

NCT04585737
View directory record Official record
Conditions
HIV I Infection
Interventions
Dolutegravir / Lamivudine Pill, Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill
Drug
Lead sponsor
Charlotte-Paige Rolle, MD
Other
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART

NCT01403051
View directory record Official record
Conditions
HIV-1 Infection
Interventions
EFV/FTC/TDF, Calcium Carbonate, Vitamin D3, Placebo for calcium carbonate, Placebo for vitamin D3
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

NCT02600819
View directory record Official record
Conditions
HIV-1 Infection
Interventions
E/C/F/TAF, B/F/TAF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • Ft. Pierce, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 3 Interventional Results available

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

NCT00112047
View directory record Official record
Conditions
HIV Infections
Interventions
Emtricitabine (FTC), Tenofovir Disoproxil Fumarate (TDF), Efavirenz (EFV), FTC/TDF, FTC/TDF/EFV, Lamivudine/zidovudine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
5
States / cities
Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2010 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract

NCT03917420
View directory record Official record
Conditions
HIV/AIDS
Interventions
Tenofovir 300Mg Oral Tablet, Emtricitabine 200 MG
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

NCT00951015
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572, efavirenz
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Bakersfield, California • Long Beach, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 21, 2026, 7:04 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sleep and Cognition After Atripla to Stribild Switch

NCT02283060
View directory record Official record
Conditions
HIV
Interventions
Stribild, Atripla
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 21, 2026, 7:04 AM EDT
Completed No phase listed Observational

Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract

NCT03218085
View directory record Official record
Conditions
HIV/AIDS, Menopause, Inflammation Vagina
Interventions
Tenofovir, Emtricitabine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1Phase 2 Interventional

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

NCT00260078
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Darunavir, Efavirenz, Nevirapine, Ritonavir, Tenofovir disoproxil fumarate, Pharmacokinetic Study
Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
21
States / cities
Alhambra, California • La Jolla, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Examining Hair to Determine Tenofovir Exposure

NCT00903084
View directory record Official record
Conditions
HIV
Interventions
Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

NCT02235662
View directory record Official record
Conditions
HIV, Contraception
Interventions
TFV IVR, TFV/LNG IVR, Placebo IVR
Drug · Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 21, 2026, 7:04 AM EDT
Terminated Phase 4 Interventional Results available

Artery Elasticity After Switch From Epzicom to Truvada

NCT00998582
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Contingency Management for PrEP Adherence and/or Methamphetamine Use

NCT04563962
View directory record Official record
Conditions
Methamphetamine-dependence, HIV-1-infection
Interventions
Contingency Management-ART, Contingency Management-Methamphetamine
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 21, 2026, 7:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks

NCT03293290
View directory record Official record
Conditions
HIV Infections
Interventions
PrEP
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 7:04 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

NCT06333808
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
51
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 21, 2026, 7:04 AM EDT